UY39295A - ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA - Google Patents

ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA

Info

Publication number
UY39295A
UY39295A UY0001039295A UY39295A UY39295A UY 39295 A UY39295 A UY 39295A UY 0001039295 A UY0001039295 A UY 0001039295A UY 39295 A UY39295 A UY 39295A UY 39295 A UY39295 A UY 39295A
Authority
UY
Uruguay
Prior art keywords
synuclein
protofibrille
binding antibodies
ban0805
antibodies
Prior art date
Application number
UY0001039295A
Other languages
English (en)
Inventor
Norström Eva
Jessica Sigvardson
Patrik Nygren
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of UY39295A publication Critical patent/UY39295A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se basa, en parte, en el descubrimiento de anticuerpos que se dirigen selectivamente a agregados de a-sinucleína humana tales como oligómeros/protofibrillas, tales como BAN0805. BAN0805 tiene una menor tendencia a fijarse a la diana de a-sinucleína monomérica no deseada en comparación con el anticuerpo monoclonal de ratón mAb47.
UY0001039295A 2020-06-26 2021-06-25 ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA UY39295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044881P 2020-06-26 2020-06-26
US202063071150P 2020-08-27 2020-08-27

Publications (1)

Publication Number Publication Date
UY39295A true UY39295A (es) 2022-01-31

Family

ID=77627146

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039295A UY39295A (es) 2020-06-26 2021-06-25 ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA

Country Status (13)

Country Link
US (2) US11339212B2 (es)
EP (1) EP4172199A1 (es)
JP (2) JP7337959B2 (es)
KR (1) KR20230027095A (es)
CN (1) CN115803341A (es)
AU (1) AU2021298222A1 (es)
CA (1) CA3181207A1 (es)
IL (1) IL298584B2 (es)
MX (1) MX2022016005A (es)
TW (1) TW202212357A (es)
UY (1) UY39295A (es)
WO (1) WO2021260434A1 (es)
ZA (1) ZA202211843B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021298222A1 (en) 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255280T3 (es) 1998-07-03 2006-06-16 Innogenetics N.V. Diagnostico diferencial de la neurodegeneracion.
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7553639B2 (en) 2006-01-31 2009-06-30 Elan Pharma International Limited Alpha-synuclein kinase
DE602007011415D1 (de) 2006-03-23 2011-02-03 Bioartic Neuroscience Ab Verbesserte protofibrilselektive antikörper und deren verwendung
JP5747414B2 (ja) * 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
CA2746778C (en) * 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
WO2011001366A1 (en) 2009-06-29 2011-01-06 Bioartic Neuroscience Ab N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease
EP2539366B1 (en) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
UY33578A (es) * 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
CA2839563C (en) * 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
DK3087098T3 (da) * 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗trem2抗体及びその使用方法
AU2021298222A1 (en) 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies

Also Published As

Publication number Publication date
JP7337959B2 (ja) 2023-09-04
KR20230027095A (ko) 2023-02-27
US20210403542A1 (en) 2021-12-30
US20230080536A1 (en) 2023-03-16
IL298584B1 (en) 2024-06-01
IL298584B2 (en) 2024-10-01
TW202212357A (zh) 2022-04-01
WO2021260434A1 (en) 2021-12-30
AU2021298222A1 (en) 2022-12-15
JP2023525174A (ja) 2023-06-15
CA3181207A1 (en) 2021-12-30
EP4172199A1 (en) 2023-05-03
CN115803341A (zh) 2023-03-14
US11339212B2 (en) 2022-05-24
JP2023159299A (ja) 2023-10-31
ZA202211843B (en) 2024-02-28
MX2022016005A (es) 2023-02-02
IL298584A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
EA202092847A1 (ru) Антитела к cd3 и их применение
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
EA202190542A1 (ru) Сконструированные биспецифические белки
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
FI3402821T3 (fi) PSMA-sitova vasta-aine ja sen käyttöjä
PE20190208A1 (es) Anticuerpos que reconocen tau
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
PE20230381A1 (es) Proteina de union a rgma
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
MX2020013606A (es) Constructos de anticuerpos multiespecificos.
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
CU20190036A7 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika
BR112022005404A2 (pt) Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap)
MX2018013306A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
UY39295A (es) ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora